2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
- PMID: 28148839
- PMCID: PMC5435119
- DOI: 10.1126/scitranslmed.aal2463
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
Abstract
2-Hydroxyglutarate (2HG) exists as two enantiomers, (R)-2HG and (S)-2HG, and both are implicated in tumor progression via their inhibitory effects on α-ketoglutarate (αKG)-dependent dioxygenases. The former is an oncometabolite that is induced by the neomorphic activity conferred by isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations, whereas the latter is produced under pathologic processes such as hypoxia. We report that IDH1/2 mutations induce a homologous recombination (HR) defect that renders tumor cells exquisitely sensitive to poly(adenosine 5'-diphosphate-ribose) polymerase (PARP) inhibitors. This "BRCAness" phenotype of IDH mutant cells can be completely reversed by treatment with small-molecule inhibitors of the mutant IDH1 enzyme, and conversely, it can be entirely recapitulated by treatment with either of the 2HG enantiomers in cells with intact IDH1/2 proteins. We demonstrate mutant IDH1-dependent PARP inhibitor sensitivity in a range of clinically relevant models, including primary patient-derived glioma cells in culture and genetically matched tumor xenografts in vivo. These findings provide the basis for a possible therapeutic strategy exploiting the biological consequences of mutant IDH, rather than attempting to block 2HG production, by targeting the 2HG-dependent HR deficiency with PARP inhibition. Furthermore, our results uncover an unexpected link between oncometabolites, altered DNA repair, and genetic instability.
Copyright © 2017, American Association for the Advancement of Science.
Conflict of interest statement
Ranjit Bindra and Peter Glazer are inventors on US patent application No. 62/344,678 submitted by Yale University, which covers compositions and methods for targeting and treating homologous recombination-deficient tumors.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5435119/bin/nihms856977f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5435119/bin/nihms856977f2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5435119/bin/nihms856977f3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5435119/bin/nihms856977f4.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5435119/bin/nihms856977f5.gif)
![Figure 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5435119/bin/nihms856977f6.gif)
Similar articles
-
Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination.Mol Cell. 2023 Jul 6;83(13):2347-2356.e8. doi: 10.1016/j.molcel.2023.05.026. Epub 2023 Jun 12. Mol Cell. 2023. PMID: 37311462 Free PMC article.
-
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors.NAR Cancer. 2021 May 17;3(2):zcab018. doi: 10.1093/narcan/zcab018. eCollection 2021 Jun. NAR Cancer. 2021. PMID: 34027408 Free PMC article.
-
IDH-Mutant Tumors Vulnerable to PARP Inhibition.Cancer Discov. 2017 Apr;7(4):OF4. doi: 10.1158/2159-8290.CD-NB2017-026. Epub 2017 Feb 22. Cancer Discov. 2017. PMID: 28228392
-
IDH mutations in cancer and progress toward development of targeted therapeutics.Ann Oncol. 2016 Apr;27(4):599-608. doi: 10.1093/annonc/mdw013. Ann Oncol. 2016. PMID: 27005468 Review.
-
Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies.Clin Cancer Res. 2021 Jan 15;27(2):383-388. doi: 10.1158/1078-0432.CCR-20-1827. Epub 2020 Sep 3. Clin Cancer Res. 2021. PMID: 32883741 Review.
Cited by
-
IDH1 mutation produces R-2-hydroxyglutarate (R-2HG) and induces mir-182-5p expression to regulate cell cycle and tumor formation in glioma.Biol Res. 2024 May 17;57(1):30. doi: 10.1186/s40659-024-00512-2. Biol Res. 2024. PMID: 38760850 Free PMC article.
-
Glioma.Nat Rev Dis Primers. 2024 May 9;10(1):33. doi: 10.1038/s41572-024-00516-y. Nat Rev Dis Primers. 2024. PMID: 38724526 Review.
-
Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review.Exp Hematol Oncol. 2024 Apr 13;13(1):40. doi: 10.1186/s40164-024-00512-8. Exp Hematol Oncol. 2024. PMID: 38615034 Free PMC article. Review.
-
Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma.JCO Precis Oncol. 2024 Mar;8:e2300544. doi: 10.1200/PO.23.00544. JCO Precis Oncol. 2024. PMID: 38547421
-
Therapeutically targeting the unique disease landscape of pediatric high-grade gliomas.Front Oncol. 2024 Mar 8;14:1347694. doi: 10.3389/fonc.2024.1347694. eCollection 2024. Front Oncol. 2024. PMID: 38525424 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous